Passage Bio Q2 2025 Earnings Report

Passage Bio EPS Results

• Actual EPS: -$2.96
• Consensus EPS: -$4.00
• Beat/Miss: Beat by +$1.04
• One Year Ago EPS: N/A

Passage Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Passage Bio Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 7:00AM ET

Passage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases of the central nervous system. The company uses adeno-associated virus (AAV) gene therapy platforms to deliver functional genes to target cells, with the goal of addressing the underlying causes of inherited neurological disorders.

Passage Bio’s development programs have included investigational therapies for conditions such as GM1 gangliosidosis, Krabbe disease and frontotemporal dementia. Its research and development activities have been supported by collaborations with the University of Pennsylvania’s Gene Therapy Program, which has contributed expertise in vector design, manufacturing and clinical development. As with other clinical-stage biotechnology companies, its product candidates remain subject to clinical testing and regulatory review and may not receive approval.

Founded in 2018 and headquartered in Philadelphia, Passage Bio has primarily served patients and research markets through its global clinical-development and biotechnology activities rather than through commercialized products. The company became publicly traded on the Nasdaq under the symbol PASG in 2020. Its programs, partnerships and corporate strategy may evolve as clinical data and regulatory developments become available.